- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01001598
Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita
Phase I/II Dose Escalation Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita
Fanconi anemia (FA) and Dyskeratosis congenita (DC) are inherited bone marrow failure syndromes. The current androgen treatments (e.g., oxymetholone) used to treat FA and DC can cause unwanted masculinizing side effects, indicating a need for a different medication. Danazol is a less potent androgen,and may therefore have fewer masculinizing side effects. Danazol is currently approved by the Food and Drug Administration (FDA) for the treatment of other diseases, but it has never been studied in patients with FA and DC.
The main purpose of this study is to see if danazol is a safe treatment for FA and DC. Specifically,we would like to determine:
- the best dose of danazol;
- how fast hemoglobin (a protein that carries oxygen in the blood) levels rise in FA and DC patients receiving danazol therapy; and
- the genetic pattern (known as expression profile) of certain cells in response to danazol, which can predict how well people respond to the medication.
Subjects who enroll in the study will be treated with danazol for up to 24 weeks (about 6 months), and will have up to 11 study visits, including followup visits at 38 weeks (9 months) and 52 weeks (one year).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eligible patients with either Fanconi anemia (FA) or Dyskeratosis congenita (DC) will initially receive danazol at a dose of 5 mg/kg/d orally, rounded to the nearest 100 mg. For the first 8 weeks, the patient will be evaluated at weeks 2, 5, and 8 for hematologic response (HR). If the patient shows a hematological response (either a hemoglobin or platelet value no longer meeting blood cell count criteria for protocol inclusion in the absence of recent transfusions)within the first 12 weeks on the initial dose, the study drug will be continued at this dose for the next 6 weeks. If the patient fails to show any hematologic response within the first 12 weeks, the dose will be escalated to 10 mg/kg/day for the next 6 weeks, and an additional monitoring visit will be required at week 14. If at week 18, the patient fails to show any hematological response on the increased dose, the dose will be increased to 15 mg/kg/day for another 6 weeks (not to exceed 800 mg/day), and an additional monitoring visit will be required at week 20. At 24 weeks, if there is no response to this dose the patient will be taken off study drug and classified as a treatment failure, and will be monitored at weeks 38 and week 52). After week 24, if the patient continues to show a response, however, the study drug may be continued at the discretion of their primary care physician, with monitoring at weeks 38 and 52.
Should the patient lose the hematologic response on 5 or 10 mg/kg/day dosing at any point within the first 18 weeks of treatment, the dose will be escalated to 10 or 15 mg/kg/day (not to exceed 800 mg/day), respectively. The patient will continue to be evaluated at the next visit. If after week 24 no hematologic improvement is seen, the patient is then taken off study drug and monitored at weeks 38 and 52.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Children's Hospital Boston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must be diagnosed with FA that is documented by a positive test for increased chromosomal breakage with mitomycin C or diepoxybutane. DC patients must have clinical features consistent with the diagnosis, abnormally short lymphocyte telomeres < 1st centile by flow-FISH evaluation, or mutation in one of the known DC genes (DKC1, TERT, TERC, TINF2, NOP10, NHP2).
- At least the following peripheral blood cytopenias: (without transfusion) Absolute neutrophil count < 500/uL or Platelet count < 30,000/uL or Hemoglobin < 8.0 gm/dl
- Negative pregnancy test by hCG testing, if of child-bearing potential.
- Agreement to use a medically approved form of birth control, if of child-bearing potential.
- Signed informed consent by the patient or legally authorized representative.
- Patients must be either 3 years of age or > 14 kg.
Exclusion Criteria:
- Malignancy
- Concurrent enrollment in any other study using an investigational drug.
- Concurrent use of anticoagulants.
- Use of androgen therapy within last three months.
- Patients with liver disease as defined by SGOT, SGPT or bilirubin greater than the upper limit of normal.
- Patients with renal disease as defined by serum creatinine greater than the upper limit of normal for age.
- Patients less than either 3 years of age or 14 kg.
- Patients who have HLA matched sibling donors.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: danazol
Subjects with either Fanconi anemia or Dyskeratosis congenita
|
Dosage is done according to weight; capsules are 50, 100, 200 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Toxicity Associated With Danazol Therapy: Virilization, and/or New or Progressive Evidence of Either Hepatic or Renal Toxicity at a Grade II Level Using National Cancer Institute Common Toxicity Criteria (NCI-CTC).
Time Frame: 48 weeks (24 weeks treatment and 24 weeks extension phase)
|
All toxicities were collected and adjudicated to definitely-related, possibly-related, or unrelated to the treatment.
|
48 weeks (24 weeks treatment and 24 weeks extension phase)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Optimal Dose and Number of Participants With Hematologic Response Rate in Fanconi Anemia (FA) and Dyskeratosis Congenita (DC) Patients Receiving Danazol Therapy
Time Frame: 12, 18 and 24 weeks
|
The optimal dose could not be calculated because the number of participants needed to do this were not enrolled. Hematologic response rate (HR) was calculated for each participant at Week 12, 18, and 24. HR was defined by hemoglobin (Hg), platelets or neutrophil response. Please find the evaluation criteria used below: Hemoglobin response: Hgb≥8 g/dL if baseline Hgb≤7 g/dL, or Hgb rise ≥1 g/dL from baseline if baseline Hgb>7 g/dL. No RBC transfusion during the 8 weeks prior to response evaluation. Platelet response: Platelet count ≥30,000/ μL if baseline platelet count ≤20,000/ μL, or platelet count rise >10,000/ μL from baseline if baseline platelet count >20,000/ μL. No platelet transfusion during the 4 weeks prior to response evaluation. ANC response: ANC count ≥1,000/ μL if baseline ANC count ≤500/ μL, or ANC count rise >500/ μL from baseline if baseline ANC count >500/ μL. |
12, 18 and 24 weeks
|
The Gene Expression Profile of Progenitor Cells in Response to Danazol, Both to Predict Responsiveness and to Screen for Small Molecules That Show a Profile Similar to That of Responsive Patients
Time Frame: Baseline and 24 weeks
|
The gene expression profiles were planned to be run on bone marrow samples collected from patients at baseline and 24 weeks but bone marrow was never collected at 24 weeks.
|
Baseline and 24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Colin A Sieff, MB.BCh, Boston Children's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Skin Diseases
- Kidney Diseases
- Urologic Diseases
- Congenital Abnormalities
- Bone Marrow Diseases
- Hematologic Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Skin Diseases, Genetic
- DNA Repair-Deficiency Disorders
- Skin Abnormalities
- Anemia, Hypoplastic, Congenital
- Anemia, Aplastic
- Congenital Bone Marrow Failure Syndromes
- Bone Marrow Failure Disorders
- Renal Tubular Transport, Inborn Errors
- Anemia
- Fanconi Syndrome
- Fanconi Anemia
- Dyskeratosis Congenita
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Estrogen Antagonists
- Danazol
Other Study ID Numbers
- 09-03-0131
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fanconi Anemia
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of Medicine; University of...TerminatedFANCONI ANEMIAUnited States
-
Rocket Pharmaceuticals Inc.RecruitingFanconi Anemia Complementation Group AUnited States
-
Rocket Pharmaceuticals Inc.Active, not recruitingFanconi Anemia Complementation Group ASpain
-
Rocket Pharmaceuticals Inc.UnknownFanconi Anemia Complementation Group AUnited States
-
Rocket Pharmaceuticals Inc.Enrolling by invitationFanconi Anemia | Fanconi Anemia Complementation Group ASpain
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...TerminatedFanconi Anemia | Severe Aplastic AnemiaUnited States
-
Cystinosis Research FoundationUnknownCystinosis | Nephropathic Cystinosis | Renal Fanconi SyndromeUnited States
-
Fairview University Medical CenterCompleted
-
Dana-Farber Cancer InstituteUnknownFanconi's AnemiaUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedPancytopenia | Fanconi's AnemiaUnited States
Clinical Trials on danazol
-
Peking Union Medical College HospitalUnknownLow/Intermediate Risk-1 MDSChina
-
Lumara Health, Inc.Completed
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedEndometrial CancerUnited States, Canada
-
FemmePharma Global Healthcare, Inc.CompletedFibrocystic Disease of BreastUnited States
-
Assistance Publique - Hôpitaux de ParisUnknownTelomere Length, Mean Leukocyte | Telomere Shortening
-
Seoul National University HospitalKyowa Kirin Korea Co., Ltd.Unknown
-
University of Southern CaliforniaRecruitingCirrhosis, Liver | CytopeniaUnited States
-
Brigham and Women's HospitalWithdrawnLung Transplant | Short Telomere Length
-
Viramal LimitedCompleted
-
IVI MadridCompleted